Publicaciones en colaboración con investigadores/as de Hadassah Medical Center (39)

2024

  1. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

    The Lancet Infectious Diseases, Vol. 24, Núm. 1, pp. e59-e68

  2. Dynamic Coronary Roadmap versus standard angiography for percutaneous coronary intervention: the randomised, multicentre DCR4Contrast trial

    EuroIntervention, Vol. 20, Núm. 3, pp. e198-e206

2023

  1. Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel

    Journal of Medical Genetics, Vol. 60, Núm. 12, pp. 1186-1197

  2. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

    The Lancet, Vol. 401, Núm. 10373, pp. 269-280

  3. Rationale and design of the Dynamic Coronary Roadmap for Contrast Reduction (DCR4Contrast) in PCI randomized controlled trial

    American Heart Journal, Vol. 263, pp. 151-158

2022

  1. Corrigendum to ‘Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study’ [European Journal of Cancer 154 (2021) 246-252] (European Journal of Cancer (2021) 154(246-252) (S0959804921004044), (10.1016/j.ejca.2021.06.029))

    European Journal of Cancer

  2. Cytomegalovirus in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021

    Transplant Infectious Disease, Vol. 24, Núm. 6

  3. ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors

    Journal of Neuroendocrinology, Vol. 34, Núm. 3

  4. Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients with Cancer: A Narrative Review

    JAMA Oncology, Vol. 8, Núm. 12, pp. 1830-1839

  5. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456

2021

  1. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study

    European Journal of Cancer, Vol. 154, pp. 246-252

  2. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

2020

  1. Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction—Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial

    American Heart Journal, Vol. 224, pp. 129-137

2019

  1. An international perspective on hospitalized patients with viral community-acquired pneumonia

    European Journal of Internal Medicine, Vol. 60, pp. 54-70

  2. International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

    Journal of Infection, Vol. 79, Núm. 4, pp. 300-311

  3. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

    Annals of Oncology, Vol. 30, Núm. 5, pp. 766-773

2018

  1. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis

    British Journal of Haematology

  2. Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals

    Clinical Microbiology and Infection, Vol. 24, Núm. 10, pp. 1070-1076

  3. Microbiological testing of adults hospitalised with community-acquired pneumonia: An international study

    ERJ Open Research, Vol. 4, Núm. 4

  4. Telotristat ethyl in carcinoid syndrome: Safety and efficacy in the TELECAST phase 3 trial

    Endocrine-Related Cancer, Vol. 25, Núm. 3, pp. 309-322